Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance. HER2-positive breast cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated in a pulse-fashion w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-11, Vol.23 (22), p.7006-7019
Hauptverfasser:	Sabbaghi, MohammadA, Gil-Gómez, Gabriel, Guardia, Cristina, Servitja, Sonia, Arpí, Oriol, García-Alonso, Sara, Menendez, Silvia, Arumi-Uria, Montserrat, Serrano, Laia, Salido, Marta, Muntasell, Aura, Martínez-García, Maria, Zazo, Sandra, Chamizo, Cristina, González-Alonso, Paula, Madoz-Gúrpide, Juan, Eroles, Pilar, Arribas, Joaquin, Tusquets, Ignasi, Lluch, Ana, Pandiella, Atanasio, Rojo, Federico, Rovira, Ana, Albanell, Joan
Format:	Artikel
Sprache:	eng
Schlagworte:	Accumulation Animals Apoptosis Apoptosis - drug effects Apoptosis - genetics Auditory defects Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer CDC2 Protein Kinase - genetics CDC2 Protein Kinase - metabolism Cell Line, Tumor Cyclin B1 Cyclin B1 - deficiency Cyclin B1 - metabolism Càncer Disease Models, Animal Drug Resistance, Neoplasm - genetics ErbB-2 protein Experimental design Explants Female G2 Phase Cell Cycle Checkpoints - drug effects G2 Phase Cell Cycle Checkpoints - genetics Humans Immunotherapy Kinases Mama Maytansine - analogs & derivatives Maytansine - pharmacology Mice Monoclonal antibodies Pharmacodynamics Pharmacology Protein Binding Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism siRNA Targeted cancer therapy Tractament Trastuzumab Trastuzumab - pharmacology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!